|
|
News Breaks | | | | February 7, 2013 | | 08:36 EDT |  | AVNR | Avanir Pharmaceuticals announces positive interim data from study with AVP-786
Avanir Pharmaceuticals announced that it has successfully completed the first of a two-stage pharmacokinetic study with AVP-786, a drug product containing a deuterium modified form of dextromethorphan. Based on interim data, Avanir believes that it has identified a formulation of AVP-786 with a comparable pharmacokinetic, safety and tolerability profile to AVP-923. The company has requested a meeting with the FDA to discuss the full development path for AVP-786. Avanir also announced today that the company intends to modify the enrollment target of its ongoing phase II clinical study of AVP-923 in central neuropathic pain in multiple sclerosis to 200 patients. As a result of this change, the company now expects to have data from the PRIME study in the fourth calendar quarter of 2013. | |
|
News For AVNR From The Last 14 Days Check below for free stories on AVNR the last two weeks. |
|
|
| May 8, 2013 | | 16:09 EDT |  | AVNR | Avanir Pharmaceuticals reports Q2 EPS (12c), consensus (9c)
 Subscribe for More Information | |
|
|
|
|
|
|
